{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T19:16:51Z","timestamp":1776107811117,"version":"3.50.1"},"reference-count":46,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["I 4328"],"award-info":[{"award-number":["I 4328"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The 2022 global outbreaks of monkeypox virus (MPXV) and increased human-to-human transmission calls for the urgent development of countermeasures to protect people who cannot benefit from vaccination. Here, we describe the development of glycovariants of 7D11, a neutralizing monoclonal IgG antibody (mAb) directed against the L1 transmembrane protein of the related vaccinia virus, in a plant-based system as a potential therapeutic against the current MPVX outbreak. Our results indicated that 7D11 mAb quickly accumulates to high levels within a week after gene introduction to plants. Plant-produced 7D11 mAb assembled correctly into the tetrameric IgG structure and can be easily purified to homogeneity. 7D11 mAb exhibited a largely homogeneous N-glycosylation profile, with or without plant-specific xylose and fucose residues, depending on the expression host, namely wild-type or glycoengineered plants. Plant-made 7D11 retained specific binding to its antigen and displayed a strong neutralization activity against MPXV, as least as potent as the reported activity against vaccinia virus. Our study highlights the utility of anti-L1 mAbs as MPXV therapeutics, and the use of glycoengineered plants to develop mAb glycovariants for potentially enhancing the efficacy of mAbs to combat ever-emerging\/re-emerging viral diseases.<\/jats:p>","DOI":"10.3390\/vaccines11071179","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T16:06:37Z","timestamp":1688141197000},"page":"1179","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A Monoclonal Antibody Produced in Glycoengineered Plants Potently Neutralizes Monkeypox Virus"],"prefix":"10.3390","volume":"11","author":[{"given":"Adrian","family":"Esqueda","sequence":"first","affiliation":[{"name":"The Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA"},{"name":"School of Life Sciences, Arizona State University, Tempe, AZ 85287, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Sun","sequence":"additional","affiliation":[{"name":"The Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Bonner","sequence":"additional","affiliation":[{"name":"The Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA"},{"name":"School of Life Sciences, Arizona State University, Tempe, AZ 85287, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huafang","family":"Lai","sequence":"additional","affiliation":[{"name":"The Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9207-7539","authenticated-orcid":false,"given":"Collin","family":"Jugler","sequence":"additional","affiliation":[{"name":"The Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA"},{"name":"School of Life Sciences, Arizona State University, Tempe, AZ 85287, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2914-7319","authenticated-orcid":false,"given":"Karen V.","family":"Kibler","sequence":"additional","affiliation":[{"name":"The Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4823-1505","authenticated-orcid":false,"given":"Herta","family":"Steinkellner","sequence":"additional","affiliation":[{"name":"Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences, 1180 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1498-7013","authenticated-orcid":false,"given":"Qiang","family":"Chen","sequence":"additional","affiliation":[{"name":"The Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA"},{"name":"School of Life Sciences, Arizona State University, Tempe, AZ 85287, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1080\/22221751.2022.2095309","article-title":"Monkeypox virus emerges from the shadow of its more infamous cousin: Family biology matters","volume":"11","author":"Xiang","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16262","DOI":"10.1073\/pnas.1005769107","article-title":"Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo","volume":"107","author":"Rimoin","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_3","unstructured":"WHO (2023, March 03). 2022\u20132023 Monkeypox Outbreak: Global Trends. Available online: https:\/\/worldhealthorg.shinyapps.io\/mpx_global\/."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"See, K.C. (2022). Vaccination for Monkeypox Virus Infection in Humans: A Review of Key Considerations. Vaccines, 10.","DOI":"10.3390\/vaccines10081342"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3201\/eid2002.130118","article-title":"Genomic variability of monkeypox virus among humans, Democratic Republic of the Congo","volume":"20","author":"Kugelman","year":"2014","journal-title":"Emerg. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nm1261","article-title":"Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus","volume":"11","author":"Golding","year":"2005","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9458","DOI":"10.1073\/pnas.1233578100","article-title":"Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses","volume":"100","author":"Belyakov","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/1743-422X-8-441","article-title":"Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease","volume":"8","author":"Golden","year":"2011","journal-title":"Virol. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41392-023-01432-5","article-title":"Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus","volume":"8","author":"Sang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1128\/JVI.02244-07","article-title":"Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine","volume":"82","author":"Benhnia","year":"2008","journal-title":"J. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.virol.2007.06.042","article-title":"Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein","volume":"368","author":"Su","year":"2007","journal-title":"Virology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7585","DOI":"10.1016\/S0021-9258(18)53215-4","article-title":"An NH2-terminal peptide from the vaccinia virus L1R protein directs the myristylation and virion envelope localization of a heterologous fusion protein","volume":"268","author":"Ravanello","year":"1993","journal-title":"J. Biol. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"8687","DOI":"10.1128\/JVI.00852-08","article-title":"Vaccinia virus l1 protein is required for cell entry and membrane fusion","volume":"82","author":"Bisht","year":"2008","journal-title":"J. Virol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1006\/viro.1995.1378","article-title":"A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies","volume":"211","author":"Wolffe","year":"1995","journal-title":"Virology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1128\/JVI.79.21.13454-13462.2005","article-title":"Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge","volume":"79","author":"Lustig","year":"2005","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1080\/19420862.2016.1227901","article-title":"Techno-economic analysis of a transient plant-based platform for monoclonal antibody production","volume":"8","author":"Nandi","year":"2016","journal-title":"mAbs"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Sun, H., Acharya, D., Paul, A.M., Lai, H., He, J., Bai, F., and Chen, Q. (2023). Antibody-Dependent Enhancement Activity of a Plant-Made Vaccine against West Nile Virus. Vaccines, 11.","DOI":"10.3390\/vaccines11020197"},{"key":"ref_18","unstructured":"Canada, H. (2022, October 25). Health Canada Authorizes Medicago COVID-19 Vaccine for Adults 18 to 64 Years of Age. Available online: https:\/\/www.canada.ca\/en\/health-canada\/news\/2022\/02\/health-canada-authorizes-medicago-covid-19-vaccine-for-adults-18-to-64-years-of-age.html."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Jugler, C., Sun, H., and Chen, Q. (2021). SARS-CoV-2 Spike Protein-Induced Interleukin 6 Signaling Is Blocked by a Plant-Produced Anti-Interleukin 6 Receptor Monoclonal Antibody. Vaccines, 9.","DOI":"10.3390\/vaccines9111365"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/pbi.13970","article-title":"A novel plant-made monoclonal antibody enhances the synergetic potency of an antibody cocktail against the SARS-CoV-2 Omicron variant","volume":"21","author":"Jugler","year":"2022","journal-title":"Plant Biotechnol. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","article-title":"Neutralizing monoclonal antibodies for treatment of COVID-19","volume":"21","author":"Taylor","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41579-022-00809-7","article-title":"SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies","volume":"21","author":"Cox","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"9404","DOI":"10.1073\/pnas.1610803113","article-title":"Glycoengineering of plants yields glycoproteins with polysialylation and other defined N-glycoforms","volume":"113","author":"Chen","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Schillberg, S., and Spiegel, H. (2022). Recombinant Proteins in Plants: Methods and Protocols, Springer.","DOI":"10.1007\/978-1-0716-2241-4"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.coviro.2021.12.005","article-title":"Development of plant-made monoclonal antibodies against viral infections","volume":"52","author":"Chen","year":"2022","journal-title":"Curr. Opin. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-chembioeng-102419-010001","article-title":"N-Glycosylation of IgG and IgG-Like Recombinant Therapeutic Proteins: Why Is It Important and How Can We Control It?","volume":"11","author":"Majewska","year":"2020","journal-title":"Annu. Rev. Chem. Biomol. Eng."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Jugler, C., Joensuu, J., and Chen, Q. (2020). Hydrophobin-Protein A Fusion Protein Produced in Plants Efficiently Purified an Anti-West Nile Virus Monoclonal Antibody from Plant Extracts via Aqueous Two-Phase Separation. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062140"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev-phyto-080417-050141","article-title":"The Rise and Rise of Nicotiana benthamiana: A Plant for All Reasons","volume":"56","author":"Bally","year":"2018","journal-title":"Annu. Rev. Phytopathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3389\/fpls.2019.00735","article-title":"Production of Biopharmaceuticals in Nicotiana benthamiana\u2014Axillary Stem Growth as a Key Determinant of Total Protein Yield","volume":"10","author":"Goulet","year":"2019","journal-title":"Front. Plant Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.chroma.2015.02.013","article-title":"Purification of monoclonal antibody against Ebola GP1 protein expressed in Nicotiana benthamiana","volume":"1389","author":"Fulton","year":"2015","journal-title":"J. Chromatogr. A"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Sun, H., Yang, M., Lai, H., Neupane, B., Teh, A.Y.-H., Jugler, C., Ma, J.K.-C., Steinkellner, H., Bai, F., and Chen, Q. (2023). A Dual-Approach Strategy to Optimize the Safety and Efficacy of Anti-Zika Virus Monoclonal Antibody Therapeutics. Viruses, 15.","DOI":"10.3390\/v15051156"},{"key":"ref_33","unstructured":"Cummings, R.D. (2023, March 03). The Consortium for Functional Glycomics. Available online: http:\/\/www.functionalglycomics.org\/."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrrheum.2017.146","article-title":"Differential antibody glycosylation in autoimmunity: Sweet biomarker or modulator of disease activity?","volume":"13","author":"Seeling","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1111\/pbi.13369","article-title":"Co-expression of human calreticulin significantly improves the production of HIV gp140 and other viral glycoproteins in plants","volume":"18","author":"Margolin","year":"2020","journal-title":"Plant Biotechnol. J."},{"key":"ref_36","first-page":"127","article-title":"Production of recombinant antigens and antibodies in Nicotiana benthamiana using \u2018magnifection\u2019 technology: GMP-compliant facilities for small- and large-scale manufacturing","volume":"375","author":"Klimyuk","year":"2014","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0042-6822(02)00038-7","article-title":"Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates","volume":"306","author":"Hooper","year":"2003","journal-title":"Virology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"105702","DOI":"10.1016\/j.isci.2022.105702","article-title":"In vitro and in vivo models for monkeypox","volume":"26","author":"Rosa","year":"2023","journal-title":"iScience"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/nbt.3556","article-title":"Plant specific N-glycans do not have proven adverse effects in humans","volume":"34","author":"Shaaltiel","year":"2016","journal-title":"Nat. Biotech."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Rup, B., Alon, S., Amit-Cohen, B.C., Brill Almon, E., Chertkoff, R., Tekoah, Y., and Rudd, P.M. (2017). Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems-The taliglucerase alfa story. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0186211"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Yang, M., Sun, H., Lai, H., Neupane, B., Bai, F., Steinkellner, H., and Chen, Q. (2023). Plant-Produced Anti-Zika Virus Monoclonal Antibody Glycovariant Exhibits Abrogated Antibody-Dependent Enhancement of Infection. Vaccines, 11.","DOI":"10.3390\/vaccines11040755"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nri.2017.106","article-title":"Beyond binding: Antibody effector functions in infectious diseases","volume":"18","author":"Lu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41577-022-00813-1","article-title":"Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection","volume":"23","author":"Zhang","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Cohen, M.E., Xiao, Y., Eisenberg, R.J., Cohen, G.H., and Isaacs, S.N. (2011). Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0020597"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/19420862.2018.1466767","article-title":"The \u201cless-is-more\u201d in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity","volume":"10","author":"Pereira","year":"2018","journal-title":"mAbs"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/bit.26503","article-title":"N-glycan engineering of a plant-produced anti-CD20-hIL-2 immunocytokine significantly enhances its effector functions","volume":"115","author":"Marusic","year":"2018","journal-title":"Biotechnol. Bioeng."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/7\/1179\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:03:28Z","timestamp":1760126608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/7\/1179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["vaccines11071179"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11071179","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,30]]}}}